H.Res. 280 · 117th Congress
Expressing the sense of the House of Representatives that decades of policies rooted in socialism have stifled United States domestic pharmaceutical drug manufacturing and left the United States exposed to the hostile actions and unfair trade practices of the People's Republic of China.
- Stage
- In committee
- Sponsor
- Ronny Jackson
- Introduced
- 2021-03-26
- Latest action
- 2021-03-29 · Referred to the Subcommittee on Health.
Subjects
Administrative law and regulatory procedures
Asia
China
Department of Health and Human Services
Health technology, devices, supplies
Competitiveness, trade promotion, trade deficits
Foreign trade and international finance
Trade agreements and negotiations
Free trade and trade barriers
Government information and archives
Prescription drugs
Competition and antitrust
Drug safety, medical device, and laboratory regulation
Food and Drug Administration (FDA)
Manufacturing